Micropoint BioScience Commitment

to Support Continued Health and Safety

During COVID-19


Micropoint is committed to responding to the COVID-19 pandemic. We have taken active measures to ensure the health and safety of our colleagues and to maintain the supply of our COVID-19 diagnostic tools in regions where they are sold.

 

Micropoint has developed two rapid, 15-minute point-of-care test for COVID-19.

 

  • The ezLabs   COVID-19 Antigen Test, a rapid in-vitro immunochromatographic assay for the qualitative detection of SARS-CoV-2 virus antigen present in human nasopharynx. 

  • The mLabs   SARS-CoV-2 IgG and IgM assay, a fluorescent microparticle immunoassay intended for the qualitative detection of the total IgC and IgM antibodies to SARS-CoV-2 in human whole blood, and plasma.

 

®

®

ezLabs COVID-19 Antigen Test

mLabs SARS-CoV IgG and IgM assay

 

 

U.S. Headquarters

 

Micropoint Bioscience, Inc.
3521 Leonard Court 
Santa Clara, CA 95054
United States

 

T:+1 (408) 588-1682
F:+1 (408) 588-1620

 

 

European Office

 

Micropoint Bioscience, Inc.

2 rue Eugene Sue

38100 Grenoble

France 

 

T: +33 6 22 38 20 48

F: +33 4 76 09 03 50

Asian Office

 

Micropoint Biotechnologies Co., Ltd.

5F, Bldg 1

Runheng Dingfeng Industrial Park, Liuxian 2 Rd.

Shenzhen 518101, Guangdong

China

 

T: +86 755 21600849

F: +86 755 86673903

Copyright Micropoint Biosciences 2016

Micropoint Bioscience products are not available for sale nor marketed in the United States at this time.